Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

被引：0
|
作者：
Couban, Stephen
Benevolo, Giulia
Donnellan, William
Cultrera, Jennifer
Koschmieder, Steffen
Verstovsek, Srdan
Hooper, Gregory
Hertig, Christian
Tandon, Maneesh
Dimier, Natalie
Templeton, Ian
Passamonti, Francesco
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4179
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
    Stephen Couban
    Giulia Benevolo
    William Donnellan
    Jennifer Cultrera
    Steffen Koschmieder
    Srdan Verstovsek
    Gregory Hooper
    Christian Hertig
    Maneesh Tandon
    Natalie Dimier
    Vikram Malhi
    Francesco Passamonti
    Journal of Hematology & Oncology, 11
  • [2] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
    Couban, Stephen
    Benevolo, Giulia
    Donnellan, William
    Cultrera, Jennifer
    Koschmieder, Steffen
    Verstovsek, Srdan
    Hooper, Gregory
    Hertig, Christian
    Tandon, Maneesh
    Dimier, Natalie
    Malhi, Vikram
    Passamonti, Francesco
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [3] FREEDOM: A phase 3b efficacy and safety study of fedrati nib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.
    Verstovsek, Srdan
    Harrison, Claire N.
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Buglio, Daniela
    Chia, Vincent
    Gerike, Torsten
    Jessent-Ciaravino, Valerie
    Mostillo, Joseph
    Zhang, Jun
    Mesa, Ruben A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
    Gupta, Vikas
    Wolleschak, Denise
    Hasselbalch, Hans
    Vannucchi, Alessandro Maria
    Koschmieder, Steffen
    Cervantes, Francisco
    Li, Yang
    Dong, Tuochuan
    Wroclawska, Monika
    Bharathy, Savita
    Harrison, Claire
    BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
  • [5] BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
    Ayala, Rosa
    Lopez, Nieves
    Abulafia, Adi Shacham
    Alwan, Maan
    Yannakou, Costas K.
    Raman, Indu
    Ribrag, Vincent
    Fong, Chun Yew
    Volchek, Yulia
    Bonifacio, Massimiliano
    Tucci, Alessandra
    Kiladjian, Jean-Jacques
    Chang, Henry
    Das, Sharmila
    Wu, Bin
    Ravindran, Palanikumar
    Shan, Vivian
    Wang, Guan
    Esposito, Oriana
    Liu, Yu
    Nikolova, Zariana
    Tehlirian, Christopher
    Coker, Shodeinde
    Lavie, David
    BLOOD, 2022, 140 : 9665 - 9667
  • [6] BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
    Lavie, David
    Ribrag, Vincent
    Loschi, Michael
    Yannakou, Costas K.
    Alwan, Maan
    Abulafia, Adi Schacham
    Hernandez-Rivas, Jesus Maria
    Volchek, Yulia
    Fong, Chun Yew
    Bonifacio, Massimiliano
    Kiladjian, Jean-Jacques
    Ianotto, Jean-Christophe
    Garcia Gutierrez, Valentin
    Tucci, Alessandra
    Xicoy, Blanca
    Al-Ali, Haifa Kathrin
    Talpaz, Moshe
    Gerber, Jonathan M.
    Raman, Indu
    Tomuleasa, Ciprian
    Lee-Hoeflich, Si Tuen
    Das, Sharmila
    Wu, Bin
    Zhao, Qian
    Kim, Eunhee
    Esposito, Oriana
    Liu, Yu
    Nikolova, Zariana
    Tehlirian, Christopher
    Coker, Shodeinde
    Ayala, Rosa
    BLOOD, 2023, 142
  • [7] Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
    Kiladjian, Jean-Jacques
    Heidel, Florian H.
    Vannucchi, Alessandro M.
    Ribrag, Vincent
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Martino, Bruno
    Kindler, Thomas
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Gopalakrishna, Prashanth
    Ide, Susan E.
    Loechner, Sabine
    Mu, Song
    Harrison, Claire N.
    BLOOD, 2014, 124 (21)
  • [8] Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
    Palandri, Francesca
    Tiribelli, Mario
    Benevolo, Giulia
    Tieghi, Alessia
    Cavazzini, Francesco
    Breccia, Massimo
    Bergamaschi, Micaela
    Sgherza, Nicola
    Polverelli, Nicola
    Crugnola, Monica
    Isidori, Alessandro
    Binotto, Gianni
    Heidel, Florian H.
    Buccisano, Francesco
    Martino, Bruno
    Latagliata, Roberto
    Spinsanti, Marco
    Kallenberg, Lydia
    Palumbo, Giuseppe Alberto
    Abruzzese, Elisabetta
    Scaffidi, Luigi
    Cuneo, Antonio
    Cavo, Michele
    Vianelli, Nicola
    Bonifacio, Massimiliano
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 285 - 290
  • [9] MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
    Bradley, Terrence
    Kuykendall, Andrew
    Komrokji, Rami S.
    Berry, Tymara
    Dougherty, Souria
    Sherman, Laurie
    Peng, Lixian
    Huang, Fei
    Wan, Ying
    Feller, Faye
    Mascarenhas, John
    BLOOD, 2022, 140 : 3941 - 3942
  • [10] Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
    Gupta, Vikas
    Yacoub, Abdulraheem
    Fazal, Salman
    Miller, Carole
    Verstovsek, Srdan
    Mesa, Ruben
    Harrison, Claire
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Mattison, Ryan
    Rein, Lindsay
    Reeves, Brandi
    Oh, Stephen
    Parameswaran, Vinod
    Deeg, Joachim
    Rose, Shelonitda
    Chia, Vincent
    Wang, Tianhua
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S331 - S332
12345